Menu
MSK-IMPACT is a targeted tissue-based sequencing test for comprehensive genomic profiling. MSK-ACCESS is a liquid biopsy test that enables non-invasive profiling and longitudinal disease monitoring. Together, they provide robust insights that help guide treatment decisions for improved outcomes in patients with advanced cancer. Unlike most tests, MSK leverages matched tumor-normal sequencing to remove germline and clonal hematopoietic variants, revealing genomic alterations of true somatic origin.
In this webinar, A. Rose Brannon, director of clinical bioinformatics at MSK, and Anita S. Bowman, associate director of clinical bioinformatics at MSK, will:
Join us at the 14th International Symposium on Minimal Residual Cancer (ISMRC) in Nice, France, where experts gather to explore the latest advancements in liquid biopsy. Discover how SOPHiA GENETICS is transforming cancer care through innovative solutions at the forefront of precision oncology. Visit our booth to learn more and connect with our team—see you there!
SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native healthcare technology company and a global leader in data-driven medicine, recently joined the European Liquid Biopsy Society (ELBS), a prestigious network consisting of partners from academia and industry with the common goal of making liquid biopsy tests part of the routine standard of care.
SOPHiA GENETICS offers a comprehensive suite of liquid biopsy applications that are helping to progress oncology research and tumor mutation profiling. Liquid biopsy offers an alternative to solid tumor testing by isolating cell-free DNA (cfDNA) from blood plasma. This testing approach allows for non-invasive cancer genomic profiling and disease monitoring, revealing critical insights in cases where tissue biopsy may not be feasible. However, liquid biopsy still faces challenges, including workflow standardization and broad adoption across the globe.
Building on the momentum of the recent launch of MSK-ACCESS® powered with SOPHiA DDM™ earlier this year, we would like to develop a community of knowledge, where peers can connect, share experiences, and hear the latest updates regarding the implementation of decentralized Memorial Sloan Kettering Cancer Center (MSK) applications.
In this webinar, attendees will:
➡️ Learn more about Memorial Sloan Kettering Cancer Center’s and
SOPHiA GENETICS’s strategies to lower liquid biopsy hurdles.
➡️ Learn more about the evolution of MSK-ACCESS® assay.
➡️ Hear about the evidence-generation efforts to demonstrate the clinical utility of MSK-ACCESS® powered with SOPHiA DDM™
➡️ Gain insights into new analytical performance data from early adopters across Europe
➡️ Get the latest updates and discuss our initiative to facilitate sample sharing among centers
We are thrilled to announce our participation in the ESMO Asia Congress 2024!
Join the SOPHiA GENETICS team at booth #E406 and explore how we are driving groundbreaking innovations in cancer research and treatment.
From our collaboration with Memorial Sloan Kettering cancer Center to decentralize MSK-ACCESS and MSK-IMPACT, to our launch of SOPHiA DDM™ Residual Acute Myeloid (RAM) Solution, we are committed to supporting clinical researchers with variant detection and analysis, biomarker discovery, and therapy selection.
We look forward to connecting with you at ESMO Asia 2024!
We are excited to invite you to join us at ESMO 2024! Find out how we advance data-driven medicine, with our cloud-based SOPHiA DDM™ Platform. Discover how it empowers health data interpretation with advanced analytics modules, simplified reporting, and a global community of healthcare institutions.
By harnessing the power of AI and multimodal data-driven analytics, we enable you to advance and streamline global access to precision therapies.
Presented by
Julien Pontis
Technical Product Manager and Lead Data Scientist at SOPHiA GENETICS
Presenter TBD
Decoding Complexity – Overcoming Real-World Challenges in Variant Analysis
Join us for the second episode of our webinar series, where we delve deeper into the complexities of variant analysis. Our esteemed bioinformatics experts will share practical solutions to real-world challenges in this field. Embark on a journey with us as we explore the advanced strategies employed by the SOPHiA DDM™ Platform to detect challenging variants associated with cancers and rare inherited disorders.
Episode 2: Advanced Techniques for Detecting Low Allele Frequency Variants
In this session, we are privileged to host two experts from SOPHiA GENETICS: Lin Song, Director of Algorithm Development, and Yvan Wenger, Manager of Bioinformatic Product Development. The focus of this webinar will be our SOPHiA DDM™ algorithm PEPPER™, which is our proprietary SNV and Indel detection technology. PEPPER™ utilizes a range of techniques to distinguish true signals from noise, ensuring precise variant calling.
Lin will highlight the strategies PEPPER™ employs to detect low allele frequency variants, by ensuring accurate distinction from library preparation and sequencing noise. This capability is crucial, especially in liquid biopsy. Yvan will present a use case demonstrating how PEPPER™ addresses the technical challenges of liquid biopsy, focusing on our application MSK-ACCESS powered with SOPHiA DDM™.
Don’t miss this chance to gain insights into our innovative methodologies for distinguishing signal from noise for low allele frequency variants.
SOPHiA GENETICS is collaborating with Memorial Sloan Kettering Cancer Center (MSK) to decentralize their advanced precision oncology tools – MSK-ACCESS® for liquid biopsy and MSK-IMPACT® for comprehensive genomic profiling (CGP). By combining the clinical expertise of MSK in cancer genomics, the predictive algorithms of SOPHiA DDMTM, and the power of the global SOPHiA GENETICS network, experts hope to expand access to precision cancer analysis capabilities worldwide.
Presented by:
Michael F. Berger, PhD, Co-Director, Marie-Josée & Henry R. Kravis Center for Molecular Oncology, Elizabeth and Felix Rohatyn Chair for Junior Faculty
Chloe Ryder, Product Manager at SOPHiA GENETICS
[et_pb_section admin_label="section"] [et_pb_row admin_label="row"] [et_pb_column type="4_4"][et_pb_text admin_label="Text"]Join us on a journey to revolutionize clinical research programs with decentralized collective intelligence. See decentralization in motion with the SOPHiA DDM™ Platform, designed to connect and integrate multimodal data from 750+ institutions across 70 countries. Learn how to unlock the platform’s potential to identify unmet needs, accelerate precision medicine development, and improve patient access to new therapies by securely sharing knowledge on a global scale. Discover how SOPHiA DDM™ continues to drive and accelerate the adoption of homologous recombination deficiency (HRD) analysis and our decentralized approach to MSK-ACCESS®.
Presented by: T. Scott Reid - VP, Global Head of Diagnostics - SOPHiA GENETICS
[/et_pb_text][/et_pb_column] [/et_pb_row] [/et_pb_section]SOPHiA GENETICS products are for Research Use Only and not for use in diagnostic procedures unless specified otherwise.
SOPHiA DDM™ Dx Hereditary Cancer Solution, SOPHiA DDM™ Dx RNAtarget Oncology Solution and SOPHiA DDM™ Dx Homologous Recombination Deficiency Solution are available as CE-IVD products for In Vitro Diagnostic Use in the European Economic Area (EEA), the United Kingdom and Switzerland. SOPHiA DDM™ Dx Myeloid Solution and SOPHiA DDM™ Dx Solid Tumor Solution are available as CE-IVD products for In Vitro Diagnostic Use in the EEA, the United Kingdom, Switzerland, and Israel. Information about products that may or may not be available in different countries and if applicable, may or may not have received approval or market clearance by a governmental regulatory body for different indications for use. Please contact us to obtain the appropriate product information for your country of residence.
All third-party trademarks listed by SOPHiA GENETICS remain the property of their respective owners. Unless specifically identified as such, SOPHiA GENETICS’ use of third-party trademarks does not indicate any relationship, sponsorship, or endorsement between SOPHiA GENETICS and the owners of these trademarks. Any references by SOPHiA GENETICS to third-party trademarks is to identify the corresponding third-party goods and/or services and shall be considered nominative fair use under the trademark law.